How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,901 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1741. Porokeratosis of Mibelli of the axillae: treatment with topical imiquimod. (Abstract)

Porokeratosis of Mibelli of the axillae: treatment with topical imiquimod. Porokeratosis of Mibelli is a rare genodermatosis characterized by a disorder of keratinization. None of the currently available therapies is effective in all cases and this situation exposes the patient to multiple treatment cycles. We describe the successful use of topical imiquimod 5% cream in the management of porokeratosis of Mibelli of the axillae in a 12-year-old girl. Treatment with imiquimod was effective

2006 Journal of Dermatological Treatment

1742. Rapid improvement of human orf (ecthyma contagiosum) with topical imiquimod cream: report of four complicated cases. (Abstract)

Rapid improvement of human orf (ecthyma contagiosum) with topical imiquimod cream: report of four complicated cases. Orf is a zoonosis caused by an epitheliotropic DNA parapox virus. Human orf is a generally benign, self-limiting condition that usually regresses in 6-8 weeks without specific treatment. However, it may be accompanied by local symptoms including pain, pruritus, lymphangitis and axillary adenitis, or less frequently by systemic symptoms such as fever or malaise. Furthermore (...) , it may be complicated by erythema multiforme, Stevens-Johnson syndrome, erysipelas, generalized mucocutaneous eruption, toxic erythema, eyelid oedema and giant, persistent or recurrent lesions in immunocompromised patients. Imiquimod, a potent topical immune response modifier, enhances both the innate and acquired immunity by stimulation of immune system cells resulting in local antiviral, antitumour and immunoregulatory activity. We present, for the first time, four complicated cases of orf

2005 Journal of Dermatological Treatment

1743. Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream. (Abstract)

Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream. A 58-year-old man was referred to our department for evaluation and treatment of a therapy-resistant pyogenic granuloma on his right third digit. This biopsy-confirmed lesion was unsuccessfully treated with shave excision and base electrocautery on two separate occasions before the patient presented to our clinic. After completing a 14-week course of twice-weekly imiquimod 5% topical application

2006 Journal of Dermatological Treatment

1744. Treatment of mammary and extramammary Paget's skin disease with topical imiquimod. (Abstract)

Treatment of mammary and extramammary Paget's skin disease with topical imiquimod. Paget's disease is an uncommon epidermal cancer, affecting all skin regions wherever apocrine glands are present. It is divided into extramammary (EMPD) and mammary Paget's disease (MPD). It can be confined to the epithelium or may be associated with an underlying adenocarcinoma. The diagnosis is confirmed by skin biopsy and the treatment depends on characteristics of the underlying cancer. Surgery is the first (...) -line treatment. Imiquimod, a topical immunomodulator, approved its efficiency in several skin neoplasms and has been shown as a safe treatment for EMPD. However, it has never been reported for the treatment of MPD.We report on two cases of EMPD and MPD successfully treated with imiquimod 5% cream.This non-surgical method may be considered as a primary treatment when Paget's disease is not associated with an underlying malignancy. The good prognosis with a long-term survival, the anatomic

2006 Journal of Dermatological Treatment

1745. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. (Abstract)

Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. Active nonintervention remains the mainstay of therapy for most uncomplicated infantile hemangiomas (IH) because of their expected involution. Topical imiquimod, with its ability to induce the production of interferon, tumor necrosis factor-alpha, and the antiangiogenesis factor tissue inhibitor of matrix metalloproteinase, has been recently reported to be efficacious in the treatment of IH.We sought to evaluate (...) the efficacy of imiquimod 5% cream in the treatment of noncomplicated IH and possible side effects.A retrospective chart review analysis was performed in 18 children (16 girls and 2 boys) with a median age of 18 weeks (range: 4-256 weeks). A total of 22 hemangiomas (14 located on head, 3 on genitalia, 2 on trunk, and 3 on extremities) were treated with imiquimod 5% cream. Imiquimod was applied 3 times weekly in 10 patients and 5 times weekly in 8 patients for a mean duration of 17 weeks (7-46 weeks).All

2007 Journal of American Academy of Dermatology

1746. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. (Abstract)

Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. Epidermodysplasia verruciformis (EV) is a rare disorder characterized by widespread human papillomavirus infection and malignant transformation. EV may be caused by mutations of the genes EVER1 or EVER2, which are located on the EV1 locus, 17q25. We describe a patient with EV and a novel homozygous gene mutation of EVER2 gene who was treated successfully with topical imiquimod.

2007 Journal of American Academy of Dermatology

1747. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. (Abstract)

Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. Topical therapeutic options for cutaneous squamous cell carcinoma in situ include 5-fluorouracil cream and imiquimod cream. Such treatment may be preferable to surgical or destructive modalities in certain anatomic locations and in instances where patients are unwilling or poor surgical candidates. We present 4 such patients (...) with cutaneous squamous cell carcinoma in situ involving a digit. Each patient failed treatment with imiquimod cream as monotherapy. In addition, two patients failed treatment with 5-fluorouracil cream as monotherapy. All 4 responded completely to 5-fluorouracil and imiquimod cream as combination therapy. In patients who have failed monotherapy with a topical agent for cutaneous squamous cell carcinoma in situ, combination treatment using both topical 5-fluorouracil cream and imiquimod cream may

2006 Journal of American Academy of Dermatology

1748. Imiquimod as an antiaging agent. (Abstract)

Imiquimod as an antiaging agent. Topical imiquimod therapy has proven to be effective for a variety of infectious, neoplastic, and inflammatory dermatologic diseases. Several published reports have validated the benefit of imiquimod therapy for actinic keratoses and superficial melanoma and nonmelanoma skin cancers. There is, however, limited evidence demonstrating the use of topical imiquimod application as an antiaging treatment.We examined the effectiveness of imiquimod 5% cream (...) in the treatment of photoaging by evaluating pretreatment and posttreatment biopsy specimens and documenting the histologic changes.This study represents an extension of an earlier project in our department in which patients with biopsy-proven lesions of lentigo maligna (LM) were recruited from a university dermatology service, a hospital, and referrals from private practitioners for an open-labeled efficacy trial with daily topical application of 5% imiquimod for 3 months. Biopsy of clinically affected skin

2007 Journal of American Academy of Dermatology

1749. Erythroplasia of Queyrat treated with imiquimod 5% cream. (Abstract)

Erythroplasia of Queyrat treated with imiquimod 5% cream. Imiquimod is an immune response-modifying agent with potent antiviral and antitumor activity effective in the treatment of various skin disorders, including in situ carcinoma of the skin (Bowen's disease). The case of a 64-year-old man affected by an in situ carcinoma of the glans mucosa, namely erythroplasia of Queyrat, successfully treated with imiquimod 5% cream is described. Because the results of tests for human papillomavirus (...) infection were negative in this case, we suggest that imiquimod may have acted through an antitumor effect mediated by cytokine activation. This compound may represent an alternative treatment in patients with erythroplasia of Queyrat, although the dosing schedule and treatment duration require further evaluation.

2006 Journal of American Academy of Dermatology

1750. Basal cell carcinoma: treatment with imiquimod. (Abstract)

Basal cell carcinoma: treatment with imiquimod. Basal cell carcinoma (BCC) is the most common cutaneous malignancy. There are various approaches to its treatment, but imiquimod, the immune response modifier, offers a topical, noninvasive, nonsurgical therapeutic option.We present our experience of the treatment of 96 patients with BCCs during the period March 2002 to February 2004 at the Dermatology Department, Hospital Clínico S. Cecilio, Granada, Spain. One hundred and forty-one tumors (...) (nodular, superficial, and pearly/ulcerated clinical types) were treated with imiquimod.The clinical cure rate at 12 months was 80-85%.Our experience indicates that imiquimod is a reasonable option for the treatment of BCC. It is low cost, can be delivered via ambulatory care, and has tolerable side-effects.

2007 International Journal of Dermatology

1751. Successful treatment of perianal Bowen's disease with imiquimod. (Abstract)

Successful treatment of perianal Bowen's disease with imiquimod. Although perianal Bowen's disease (BD) is a relatively uncommon malignancy, it is being detected with increasing frequency. It has a strong tendency for local recurrence and treatment remains controversial. The effectiveness of different treatment modalities, ranging from aggressive wide local excision with skin grafting to the application of a topical immune response modifier, remains uncertain. To our knowledge only two cases (...) of perianal BD, successfully treated with imiquimod, have been reported. We wish to present the third case, effectively treated with imiquimod.

2007 International Journal of Dermatology

1752. Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids. (Abstract)

Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids. Imiquimod 5% cream has been found to be effective and safe in preventing recurrence of keloids on earlobes after excision. We evaluated the efficacy and safety of imiquimod 5% cream in preventing the recurrence of presternal keloids after excision (3 keloids in 2 patients). After excision with radiofrequency, imiquimod 5% cream was applied once daily at bedtime for 8 weeks, and the defect was left to heal (...) by secondary intention. In all the treated keloids, the defect healed in 6-8 weeks, and no recurrence was seen while on imiquimod application; however, all keloids completely recurred within 4 weeks of stopping imiquimod. Side effects were mild and acceptable in the form of burning and pain. Imiquimod did exert an antifibrotic action but it was short-lived.2007 S. Karger AG, Basel

2007 Dermatology

1753. 5% topical imiquimod tolerance in transplant recipients. (Abstract)

5% topical imiquimod tolerance in transplant recipients. Topical imiquimod is a new immunomodulator agent approved for genital warts, actinic keratosis (AK) or carcinoma, occurring in immunocompetent patients.This study aimed to assess the safety and efficacy of imiquimod for the treatment of warts, AK and bowenoid papulosis (BP) in transplant patients.24 transplant patients (18 kidney, 4 kidney-pancreas and 2 heart) were included in this retrospective study conducted between June 2000 (...) and February 2003 at the department of dermatology of 3 hospitals. Imiquimod cream was applied 3 times a week over a median period of 9 weeks.Graft function was not altered under therapy. Local tolerance was excellent. Complete responses were observed in 1 patient (1/12) with cutaneous warts and 1 (1/6) with AK. Two patients of 3 with BP had total clearance of their lesions. Partial responses were observed in 3 of the 6 AK-treated patients, 5 of 12 patients with cutaneous warts and 1 of 2 patients

2007 Dermatology

1754. Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. (Abstract)

Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. Viral warts may cause significant morbidity in individuals unable to mount an adequate T-helper 1 cell-mediated immune response to human papillomavirus. Imiquimod is a potent inducer of antiviral cytokine activity which has shown significant efficacy in the treatment of genital warts. Similar efficacy in cutaneous warts is not yet established.To assess the response of persistent cutaneous warts to 5% imiquimod (...) cream in immunosuppressed individuals.Fifteen immunosuppressed patients with warts on the hands and/or feet present for more than 18 months, which had failed to respond to a minimum of 12 weeks of topical salicylic acid and four cycles of cryotherapy, were recruited. Imiquimod 5% cream was applied in an open label, right vs. left comparison study for 24 weeks (three times weekly for 8 weeks, daily for 8 weeks, then daily with occlusion for 8 weeks).Twelve (80%) patients completed the study protocol

2005 British Journal of Dermatology

1755. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. (Abstract)

Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Nonmelanoma skin cancer represents a significant cause of morbidity in organ transplant recipients (OTRs). Cutaneous malignancies, mainly invasive squamous cell carcinoma and its precursor actinic keratosis (AK), appear approximately 5-10 years after organ transplantation. Impaired wound healing and high recurrence rates in immunocompromised patients treated (...) with destructive therapies such as cryosurgery or topical 5-fluorouracil represent frequently known complications.To evaluate the safety and efficacy of imiqimod 5% in the treatment of AKs in OTRs.Six OTRs (two kidney, two heart, one lung and one liver) with extensive AKs were treated with imiquimod 5% cream two to three times weekly in an open-label uncontrolled, nonrandomized pilot study.In five of six patients treated with imiquimod 5% cream all AK lesions were cleared after 12-16 weeks. One patient showed

2006 British Journal of Dermatology

1756. Imiquimod in the treatment of lentigo maligna. (Abstract)

Imiquimod in the treatment of lentigo maligna. Lentigo maligna (LM) is treated to prevent progression to lentigo maligna melanoma (LMM). Surgery remains the treatment of choice, although topical immunotherapy with imiquimod has recently become a popular alternative.In this review, we have analysed the published literature relating to the use of imiquimod for LM, in order to understand better the utility of this treatment.All English language studies relating to the use of imiquimod for LM were (...) analysed up to January 2006.Eleven case reports and four open-label studies were identified, comprising a total of 67 patients who completed treatment with imiquimod for LM. There was significant variability in treatment schedules and regimens. Eight patients failed to respond, with LMM developing in two of these. In certain cases there were discrepancies between clinical and histological response with some patients clearing clinically but not histologically, and vice versa. Follow-up periods were

2006 British Journal of Dermatology

1757. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Full Text available with Trip Pro

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Patients with metastatic skin disease in malignant melanoma can be difficult to treat effectively, often requiring repeated treatments with different modalities in an attempt to control their disease. Treatment of nonsurgically resectable melanoma deposits is unsatisfactory, as they are often multiple and recurring. Anecdotal evidence from individual use (...) of imiquimod in superficial metastases and intralesional interleukin (IL)-2 in subcutaneous deposits suggests that the combination may be more effective in bulky subcutaneous disease.To investigate the combination of topical imiquimod and, for selected lesions, intralesional IL-2, to treat a small cohort of patients with accessible melanoma metastases resistant to other treatments.Thirteen patients were recruited: all had evidence of multiple cutaneous and/or subcutaneous metastases. Imiquimod was applied

2007 British Journal of Dermatology

1758. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. (Abstract)

Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Imiquimod 5% cream is approved in the USA, Europe and Australia to treat superficial basal cell carcinoma, using a regimen of once daily, 5 times per week for 6 weeks. Vehicle-controlled, phase III clinical trials show that imiquimod is safe and effective for treating superficial basal cell carcinoma with dosing 5 or 7 times (...) were evaluated for recurrence at the 3-, 6-, 12- and 24-month follow-up visits. The initial clearance rate at 12 weeks post treatment was 94.1%. The proportion of subjects who were clinically clear at the 2-year follow-up visit was estimated to be 82.0%. Imiquimod was tolerated when applied daily, with erythema reported for all subjects participating in the study. The recurrence rate observed suggests that once daily dosing and 5x/week dosing yield similar clearance rates, but daily dosing

2006 Australasian Journal of Dermatology

1759. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. (Abstract)

An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. SUMMARY The short-term efficacy of imiquimod 5% cream for the treatment of primary superficial basal cell carcinoma has been established. This study investigated its efficacy following curettage (without electrodesiccation) for the treatment of primary nodular basal cell carcinoma on the trunk and limbs. Seventeen patients with a total of 34 (...) lesions were enrolled. Curettage was used to de-bulk the lesion and confirm suitable histology. Lesions displaying more aggressive subtypes (such as micronodular or morpheoic components) were excluded. Lesions were treated daily for 6 to 10 weeks with imiquimod 5% cream. Three months post treatment all lesions were excised, and 32 of 34 treated lesions (94%) were histologically clear of basal cell carcinoma. Fourteen of 17 patients rated the cosmetic outcome of treatment as excellent or good

2006 Australasian Journal of Dermatology

1760. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Full Text available with Trip Pro

Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. There has been considerable research into the safety and efficacy of topical 5% imiquimod cream for the treatment of skin cancers in recent years, in particular superficial and nodular basal cell carcinomas. However, there are limited long-term follow-up studies. This retrospective study aims to determine the efficacy of 5% imiquimod cream in the treatment of facial basal cell (...) carcinomas over 3 years. Medical records of 12 patients treated with 5% imiquimod cream at a private dermatology practice during 2001 and 2002 were retrospectively reviewed. Target tumours included superficial and nodular basal cell carcinomas, giving a total lesion number of 19. Patients were commenced on a once daily treatment regimen for up to 9 weeks, and given rest periods as required according to the severity of application site reactions. We found that 5% imiquimod cream is an effective treatment

2006 Australasian Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>